2025-09-15 - Analysis Report
Okay, here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the data you provided, presented as a concise report:

## SDGR (Schrodinger Inc.) Analysis

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO):**

*   **SDGR Cumulative Return:** -55.97%
*   **VOO Cumulative Return:** 60.59%
*   **Absolute Divergence:** -118.6% (SDGR significantly underperformed the S&P 500)
*   **Relative Divergence:** 0.0 (This indicates SDGR's performance is at the lowest end of its historical range relative to VOO)

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
|------------|---------|-------|----------|--------|--------|
| 2020-2022  | -74.0%  | 68.9% | -89.0%   | -0.1   | 1.4    |
| 2021-2023  | -65.0%  | 68.9% | -83.0%   | -0.0   | 2.6    |
| 2022-2024  | 8.0%   | 72.4% | -17.0%   | -0.0   | 1.4    |
| 2023-2025  | -3.0%  | 74.0% | -59.0%   | -0.0   | 1.4    |

**Analysis:**  The alpha/beta analysis shows negative alpha values across all periods, indicating underperformance relative to the market. The beta values are close to zero, suggesting a weak correlation with the market. The CAGR is showing a huge underperformance

**2. Recent Stock Price Action:**

*   **Current Price:** \$18.57
*   **Previous Close:** \$18.78
*   **Change:** -1.12%
*   **5-day Moving Average:** \$18.88
*   **20-day Moving Average:** \$19.36
*   **60-day Moving Average:** \$20.30

**Analysis:** The current price is below all three moving averages, suggesting a short-term downtrend.  The negative change from the previous close confirms recent downward pressure.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 31.99 (Approaching oversold territory)
*   **PPO:** -0.2066 (Negative, indicating a downtrend)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence (20-day):** -0.5 (Short-term decline)
*   **Expected Return (%):** -6265.3%

**Analysis:** The low MRI suggests that the overall market risk is low. The oversold RSI could indicate a potential for a short-term bounce. However, the negative PPO and Delta divergence suggest continued downward momentum. The extremely negative expected return should be viewed with extreme skepticism, as it is likely a product of the model used and recent performance.

**4. Recent News & Events:**

*   Valuation being evaluated amid quiet market sentiment.
*   Analyst potential rally target of 40.43%.
*   Company presentation at a healthcare conference.
*   Inducement grants reported.
*   Discontinuation of a program (SGR-2921).

**Analysis:** Recent news is mixed. While some articles suggest potential upside ("rally"), the discontinuation of a program and valuation concerns raise red flags.

**4-2. Analyst Opinions:**

*   **Consensus:** Strong Buy (~1.38)
*   **Target Price (avg/high/low):** \$28.11 / \$33.00 / \$19.00
*   **Recent Rating Changes:** No changes listed.

**Analysis:** Analyst consensus is surprisingly strong given the stock's recent performance. The average target price suggests significant upside potential from the current price. However, it's crucial to consider that analyst ratings can lag behind actual performance.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-08-06 | -0.59 | 0.05 B$     |
| 2025-05-07 | -0.82 | 0.06 B$     |
| 2024-11-12 | -0.52 | 0.04 B$     |
| 2024-07-31 | -0.74 | 0.05 B$     |
| 2025-08-06 | -0.74 | 0.05 B$     |

**Analysis:**  The company consistently reports negative EPS. Revenue is relatively stable. This suggests a lack of profitability.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | \$0.05B | 47.77%        |
| 2025-03-31   | \$0.06B | 52.26%        |
| 2024-12-31   | \$0.09B | 72.61%        |
| 2024-09-30   | \$0.04B | 50.24%        |
| 2024-06-30   | \$0.05B | 66.20%        |

Capital and Profitability:

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-06-30   | \$0.34B | -12.59%  |
| 2025-03-31   | \$0.37B | -16.01%  |
| 2024-12-31   | \$0.42B | -9.54%   |
| 2024-09-30   | \$0.45B | -8.49%   |
| 2024-06-30   | \$0.47B | -11.40%  |

**Analysis:** While the company demonstrates high-profit margins, it's not translating into overall profitability as ROE is negative. Equity is also declining, which suggests that the company is burning through cash.

**7. Overall Assessment:**

SDGR's recent performance is concerning. It has significantly underperformed the S&P 500, exhibits negative profitability, and has a declining equity base. While analysts maintain a "Strong Buy" consensus, the stock is trading well below their target price. The recent news is mixed, with some positive notes offset by program discontinuation and valuation concerns.

**Investment Recommendation:**

Given the information available, a *highly cautious* approach is warranted. While the oversold RSI and analyst target prices suggest potential upside, the fundamental issues (negative earnings, declining equity) and negative performance relative to the market are significant concerns.

**Disclaimer:** This is an analysis based on the provided data and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions.
